Skip to main
CGTX

Cognition Therapeutics (CGTX) Stock Forecast & Price Target

Cognition Therapeutics (CGTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cognition Therapeutics Inc has demonstrated a significant year-to-date stock increase of approximately 90%, outperforming the XBI index, while maintaining an attractive valuation with an estimated enterprise value of less than $90 million. The company's lead product candidate, zervimesine (CT1812), has shown promising efficacy in clinical trials, including an 82% reduction in total neuropsychiatric inventory scores, indicating a positive impact on the quality of life for patients with Alzheimer's disease and related disorders. Additionally, zervimesine's ability to penetrate the blood-retina barrier with oral administration suggests it could provide a more tolerable and effective long-term treatment option compared to current therapies requiring invasive procedures, enhancing the drug's potential market appeal.

Bears say

Cognition Therapeutics faces a challenging road ahead, primarily due to significant risks associated with the clinical development of its lead product candidate, CT1812, which may encounter negative safety and efficacy findings that could prompt downward revisions to financial projections. The company's ability to advance CT1812 into pivotal trials and secure necessary regulatory approvals is uncertain, placing additional pressure on its growth prospects and possibly leading to unfavorable commercial performance. Furthermore, the presence of intense competition from existing and emerging therapies in similar indications amplifies the risk of limited market penetration and pricing challenges, further contributing to a negative outlook for Cognition Therapeutics's stock.

Cognition Therapeutics (CGTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cognition Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cognition Therapeutics (CGTX) Forecast

Analysts have given Cognition Therapeutics (CGTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cognition Therapeutics (CGTX) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cognition Therapeutics (CGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.